Archive: June 2018

Bipolar Androgen Therapy in the Treatment of Prostate Cancer

Samuel Ray Denmeade, MD

  H&O  What is bipolar androgen therapy (BAT)? SD  BAT consists of the administration of a high dose of androgen—also called testosterone—in an effort to control […]

Cellular Immunotherapy for Non-Hodgkin Lymphoma

Catherine Bollard, MD, MBChB

  H&O  What types of cellular immunotherapy are being investigated in non-Hodgkin lymphoma? CB  It is important to distinguish between the types of cellular immunotherapy available […]

Management of Newly Diagnosed or Recurrent Ovarian Cancer

Ursula A. Matulonis, MD

  Abstract: The treatment of newly diagnosed or recurrent ovarian cancer has changed significantly in recent years, with an increased number of treatment options available. Surgery […]

Contemporary Management of Advanced Renal Cell Carcinoma

Abhinav Khanna, MD, Alice Crane, MD, Nitin Yerram, MD, Daniel Sun, MD, Kyle Ericson, MD, Scott D. Lundy, MD, PhD, and Robert Abouassaly, MD

  Abstract: Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease […]

A Closer Look at Blinatumomab

Ryan J. Mattison, MD 

  On March 29, 2018, blinatumomab (Blincyto, Amgen) received an accelerated expanded approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic […]

Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium

Commentary by Robert A. Figlin, MD

Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 8-10, 2018 • San Francisco, California Atezolizumab Plus Bevacizumab Improves Progression-Free Survival […]

Hem/Onc News

Devon Schuyler

Osimertinib Approved for First-Line Treatment in Metastatic NSCLC On April 18, the US Food and Drug Administration (FDA) approved osimertinib (Tagrisso, AstraZeneca) for the first-line treatment […]

The Fast-Changing World of CLL

Brad S. Kahl, MD

  Do you remember when CLL was managed largely with chlorambucil? The big decision was whether to give the agent daily or in pulses every two […]

Back to Archive